Who makes Oncoquest-L vaccine?

Oncoquest-L vaccine is developed by XEME Biopharma Inc..

What development phase is Oncoquest-L vaccine in?

Oncoquest-L vaccine is in Phase 2.

Last reviewed 2026-05-15 · How we verify

Oncoquest-L vaccine

XEME Biopharma Inc. · Phase 2 active Biologic

At a glance

Generic name	Oncoquest-L vaccine
Sponsor	XEME Biopharma Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oncoquest-L vaccine CI brief — competitive landscape report
Oncoquest-L vaccine updates RSS · CI watch RSS
XEME Biopharma Inc. portfolio CI